Ashurst is advising Morgan Stanley & Co. International plc (“Morgan Stanley”) in relation to the £958 million offer for Vectura Group plc (“Vectura”) by Murano Bidco Limited (“Bidco”), a newly incorporated company indirectly controlled by funds managed by The Carlyle Group Inc. (“Carlyle”).
Carlyle is a global investment firm with US$260 billion of assets under management which deploys private capital across three business segments: Global Private Equity, Global Credit and Investment Solutions.
Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. Viking has thirteen key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development.
Morgan Stanley is acting as financial adviser to Bidco in relation to the offer.
The Ashurst team is being led by partners Karen Davies and Tim Rennie, assisted by senior associates Jake Hadfield, Sebastian Brignell and Jenny Choi and associate Krishna Parikh.